---
schema_version: "secwatch.filing_event.v1"
accession: "0001770787-22-000004"
form_type: "8-K"
ticker: "TXG"
cik: "0001770787"
company_name: "10x Genomics, Inc."
filed_at: "2022-02-16T23:59:59+00:00"
generated_at: "2026-06-27T07:36:17.965974+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# 10x Genomics reports FY 2021 revenue $490.5M (+64% YoY); guides FY 2022 revenue $600-630M

## Summary
- Revenue $490.5M FY 2021, up 64% from $298.8M in FY 2020; Q4 revenue $143.5M, up 28% from $112.2M.
- Gross margin 85% FY 2021 vs 80% in 2020, due to lower royalties and manufacturing efficiencies.
- Operating loss $52.3M FY 2021 vs $534.1M in 2020, which included $447.5M acquisition-related R&D charges.
- Net loss $58.2M FY 2021 vs $542.7M in 2020; cash and equivalents $587.4M as of Dec 31, 2021.
- FY 2022 revenue guidance $600-630M, representing 22-28% growth over FY 2021.

## SEC filing metadata
- accession: 0001770787-22-000004
- form_type: 8-K
- ticker: TXG
- cik: 0001770787
- company_name: 10x Genomics, Inc.
- filed_at: 2022-02-16T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/0001770787-22-000004-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1770787/000177078722000004/txg-20220216.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001770787-22-000004
- JSON: https://secwatch.observer/filing/0001770787-22-000004.json
- Plain text: https://secwatch.observer/filing/0001770787-22-000004.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.